Abstract 1385P
Background
Selective RET inhibitors transformed the treatment (tx) paradigm of RET fusion-positive (RET+) lung cancers. For selpercatinib, the median progression free survival (PFS) is 22.0 months (mos) for tx naive patients and 24.9 mos for platinum doublet pretreated patients. Genomic factors associated with early versus late progression are unknown.
Methods
We analyzed data from 80 patients with RET+ LC identified between January 2014 and March 2023 utilizing a DNA-based hybrid capture tumor next generation tumor sequencing assay (MSK-IMPACT) and plasma ctDNA assay (MSK-ACCESS). Patients with radiologic progression (PD) on selpercatinib ≤ 3 mos from initiation were classified as “rapid progressors”, >3- 24 mos as “intermediate progressors”, and ≥24 months as“late progressors.” Baseline and post-PD MSK-IMPACT and MSK-ACCESS specimens were evaluated. Patients with post-PD biopsies were evaluated for acquired resistance (AR) (classified as on-target (secondary RET mutations), off-target (non-RET OncoKB level 1-4), and unknown).
Results
Among 80 patients with RET+ LC, 63 had pre-tx tumor sequencing and 35 patients had post-tx tumor/ctDNA sequencing. 58% (n=46/80) progressed on selpercatinib. PD was classified as rapid, intermediate, and late in 9% (n=7), 35% (n=28), 14% (n=11), respectively. Acquired resistance (AR) was identified in 48% of cases. Six patients had on-target AR and 17 patients had off-target AR. Most common off-target AR included MET amp (9%), KRAS mutation (6%), PIK3CA mutation (6%), CDKN2A mutation (6%), and FGFR1 amp (6%). There were no differences in age, gender, ethnicity, prior tx, or PDL1 status between these groups. Pre-tx TP53, KEAP1, and ARID1A mutations were more common in rapid and intermediate versus late PD (p=0.03, p=0.02, p=0.06). Off-target mechanisms of resistance appeared to be enriched in rapid and early progressors vs late progressors (75% vs 51% vs 25%, p=0.3).
Conclusions
RET fusion+ NSCLCs that progressed on selpercatinib prior to two years, an approximation of the drug’s median PFS, were enriched for select co-occurring alterations (e.g., TP53, KEAP1, and ARID1A mutations) in pre-tx samples and off-target resistance in post-PD samples.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
R01 CA251591.
Disclosure
E. Rosen: Financial Interests, Personal, Research Funding: Bayer. S.R. Yang: Financial Interests, Personal, Other, Honoraria: Prime Education; Financial Interests, Personal, Advisory Role: InVitae. M.G. Kris: Financial Interests, Personal, Research Grant: Boehringer Ingelheim, National Lung Cancer Partnership, Pfizer, Puma, Stand up to cancer; Financial Interests, Personal, Speaker, Consultant, Advisor: Ariad, AstraZeneca, Bind Biosciences, Boehringer Ingelheim, Chugai Pharma, Clovis, Covidien, Daiichi Sankyo, Genentech, Novartis, Millenium, Pfizer, Roche. A. Drilon: Financial Interests, Personal, Advisory Board: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millennium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, BeiGene, BerGenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem Oncology, More Health, AbbVie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX, Amgen, Janssen, EcoR1, Monte Rosa; Financial Interests, Personal, Other, CME: Medscape, Onclive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, PeerView Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Medscape, Clinical Care Options, AiCME; Financial Interests, Personal, Other, CME, Consulting: Axis; Financial Interests, Personal, Other, Consulting: Nuvalent, Merus, EPG Health, mBrace, Harborside Nexus, Ology, TouchIME, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc; Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical, Remedica Ltd, RV More; Financial Interests, Personal, Stocks/Shares: Treeline Biosciences; Financial Interests, Personal, Royalties: Wolters Kluwer; Financial Interests, Personal, Other, stocks: mBrace; Financial Interests, Institutional, Funding, Research funding: Pfizer, Exelixis, PharmaMar, GSK, Teva, Taiho; Financial Interests, Personal, Funding, Research: Foundation Medicine; Non-Financial Interests, Member: ASCO, AACR, IASLC; Other, Food/Beverage: Merck, PUMA, Merus; Other: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20